213 related articles for article (PubMed ID: 8954023)
1. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
[TBL] [Abstract][Full Text] [Related]
3. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
[TBL] [Abstract][Full Text] [Related]
4. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
[TBL] [Abstract][Full Text] [Related]
5. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
6. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
7. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
[TBL] [Abstract][Full Text] [Related]
8. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
Svensson J; Lönn L; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Boseaus I; Sjöström L; Bengtsson BA
J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
[TBL] [Abstract][Full Text] [Related]
9. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
Nass R; Pezzoli SS; Oliveri MC; Patrie JT; Harrell FE; Clasey JL; Heymsfield SB; Bach MA; Vance ML; Thorner MO
Ann Intern Med; 2008 Nov; 149(9):601-11. PubMed ID: 18981485
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of pulsatile growth hormone secretion by continuous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults--a clinical research center study.
Chapman IM; Hartman ML; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1996 Aug; 81(8):2874-80. PubMed ID: 8768844
[TBL] [Abstract][Full Text] [Related]
11. Increases in circulating insulin-like growth factor I levels by the oral growth hormone secretagogue MK-0677 in the beagle are dependent upon pituitary mediation.
Schleim KD; Jacks T; Cunningham P; Feeney W; Frazier EG; Niebauer GW; Zhang D; Chen H; Smith RG; Hickey G
Endocrinology; 1999 Apr; 140(4):1552-8. PubMed ID: 10098487
[TBL] [Abstract][Full Text] [Related]
12. Repeat administration of the GH secretagogue MK-0677 increases and maintains elevated IGF-I levels in beagles.
Hickey GJ; Jacks TM; Schleim KD; Frazier E; Chen HY; Krupa D; Feeney W; Nargund RP; Patchett AA; Smith RG
J Endocrinol; 1997 Feb; 152(2):183-92. PubMed ID: 9071975
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects.
Aloi JA; Gertz BJ; Hartman ML; Huhn WC; Pezzoli SS; Wittreich JM; Krupa DA; Thorner MO
J Clin Endocrinol Metab; 1994 Oct; 79(4):943-9. PubMed ID: 7962302
[TBL] [Abstract][Full Text] [Related]
14. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
Khorram O; Laughlin GA; Yen SS
J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
[TBL] [Abstract][Full Text] [Related]
15. Unequal impact of short-term testosterone repletion on the somatotropic axis of young and older men.
Gentili A; Mulligan T; Godschalk M; Clore J; Patrie J; Iranmanesh A; Veldhuis JD
J Clin Endocrinol Metab; 2002 Feb; 87(2):825-34. PubMed ID: 11836328
[TBL] [Abstract][Full Text] [Related]
16. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
[TBL] [Abstract][Full Text] [Related]
17. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women--a clinical research center study.
Friend KE; Hartman ML; Pezzoli SS; Clasey JL; Thorner MO
J Clin Endocrinol Metab; 1996 Jun; 81(6):2250-6. PubMed ID: 8964860
[TBL] [Abstract][Full Text] [Related]
18. Fasting suppresses pulsatile luteinizing hormone (LH) secretion and enhances orderliness of LH release in young but not older men.
Bergendahl M; Aloi JA; Iranmanesh A; Mulligan TM; Veldhuis JD
J Clin Endocrinol Metab; 1998 Jun; 83(6):1967-75. PubMed ID: 9626127
[TBL] [Abstract][Full Text] [Related]
19. Effect of aging on the sensitivity of growth hormone secretion to insulin-like growth factor-I negative feedback.
Chapman IM; Hartman ML; Pezzoli SS; Harrell FE; Hintz RL; Alberti KG; Thorner MO
J Clin Endocrinol Metab; 1997 Sep; 82(9):2996-3004. PubMed ID: 9284733
[TBL] [Abstract][Full Text] [Related]
20. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
